Clinical Scorecard: Clinical Features, Treatment Approaches, and Survival Rates in Ductal Adenocarcinoma of the Prostate: A Retrospective Multicenter Study
At a Glance
Category
Detail
Condition
Ductal Adenocarcinoma of the Prostate
Key Mechanisms
Aggressive histologic subtype with poorer prognosis compared to acinar adenocarcinoma.
Target Population
Men diagnosed with prostatic ductal adenocarcinoma.
Care Setting
High-volume urological centers
Key Highlights
PDA is associated with advanced stages at diagnosis and higher ISUP grades.
Lower serum PSA concentrations may contribute to underdiagnosis of PDA.
Overall survival for metastatic PDA is 72% at 5 years.
Presence of ductal components in biopsies correlates with increased risks of biochemical recurrence.
Guideline-Based Recommendations
Diagnosis
Histological confirmation of prostatic ductal adenocarcinoma is essential.
Management
Treatment planning should consider the aggressive nature of PDA.
Monitoring & Follow-up
Follow-up should include assessment of biochemical recurrence and survival outcomes.
Risks
PDA is associated with increased disease-specific mortality and metastases to atypical locations.
Patient & Prescribing Data
82 patients with histologically confirmed PDA.
Therapeutic data included systemic and local treatments post-local therapy.
Clinical Best Practices
Accurate recognition of PDA is crucial for treatment planning.
Consideration of ductal differentiation in routine clinical practice.
by A. Handke, P. Paffenholz, K. Schlack, K. E. Seifert, J. Linxweiler, J. Mink, F. Flockerzi, T. Nestler, M. Wenzel, C. Siech, C. Darr, V. Grünwald, F. Roghmann, K. H. Tully
An updated clinical practice guideline from the American Society for Radiation Oncology substantially expands and modernizes recommendations for the use of radiation therapy in pancreatic cancer.
